- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Joyce A. O’Shaughnessy | Authors
Early-Stage Monitoring and Adverse Event Mitigation for Patients with HER2-Postitive Breast Cancer
October 27, 2022
Dr. Joyce O’Shaughnessy closes the discussion with considerations for clinicians on monitoring patients with HER2-psotive breast cancer.
Discussing Treatment and Management Strategies with Patients in the HER2-Positive Setting
October 20, 2022
Advice for clinicians on how to discuss treatment and management strategies with patients with HER2-postitive breast cancer.
The Impact of COVID-19 on Treatment Decisions Across Patients with HER2-Positive Breast Cancer
October 20, 2022
Discussion centered around the how the COVID-19 pandemic has influenced clinical treatment decisions across patients with HER2-positive breast cancer.
Data Review and Key Insights: The FeDeriCa Trial and PHranceSCa Study
October 13, 2022
Dr. Joyce O’Shaughnessy briefly reviews and provides insights into the FeDeriCa and the PHranceSCa studies.
Pertuzumab and Trastuzumab: Patient Eligibility, Administration Methods, and Dosing Strategies
October 13, 2022
Clinical insights concerning the administration of combination pertuzumab/trastuzumab/hyaluronidase-zzxf for patients with HER2-positive breast cancer.
A Generalized Approach to First-Line HER2-Positive Breast Cancer Treatment
October 07, 2022
A breast cancer expert shares the current first-line standard of care for patients with HER2-positive breast cancer and presents scenarios where the standard treatment approach may not be appropriate.
The HER2-Positive Breast Cancer Landscape
October 07, 2022
Joyce O’Shaughnessy, MD shares an overview of the HER2-positive breast cancer landscape, focusing on prognosis and risk of recurrence for patients with early-stage and metastatic breast cancer.